1,778
Views
4
CrossRef citations to date
0
Altmetric
Drug Evaluation

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

Pages 301-311 | Received 26 Nov 2017, Accepted 14 Feb 2018, Published online: 22 Feb 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Karl Sebastian Johansson, David Peick Sonne, Filip Krag Knop & Mikkel Bring Christensen. (2020) What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline. Expert Opinion on Drug Discovery 15:11, pages 1253-1265.
Read now
Sander Lefere, Lindsey Devisscher & Frank Tacke. (2020) Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opinion on Investigational Drugs 29:2, pages 89-92.
Read now
Miao Miao, Erik De Clercq & Guangdi Li. (2020) Clinical significance of chemokine receptor antagonists. Expert Opinion on Drug Metabolism & Toxicology 16:1, pages 11-30.
Read now
Frank Tacke & Ralf Weiskirchen. (2018) An update on the recent advances in antifibrotic therapy. Expert Review of Gastroenterology & Hepatology 12:11, pages 1143-1152.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.